Lupin has licensed two oncology drug candidates, LNP7457 and LNP8701, to US-based Kaveri Therapeutics. In exchange, the pharmaceutical firm secured an 82.2% stake in the newly formed entity. This move allows Lupin to offload the costs of future clinical trials while retaining a significant ownership interest in the development of treatments for solid tumors.
Detailed Coverage
Pharmaceutical major Lupin Limited has entered into a strategic licensing agreement through its US subsidiary, Lupin Inc., to advance two oncology drug programs. Under the terms of the deal finalized on July 20, 2026, the company has licensed its exclusive rights for LNP7457 and LNP8701 to Kaveri Therapeutics Inc., a newly incorporated clinical-stage firm based in Delaware.
Equity Stake and Deal Structure
Lupin Inc. has received an 82.2% equity stake in Kaveri Therapeutics, valued at $1.6 million, along with 332,000 common shares. This structure allows the company to participate in the future upside of these drug candidates while shifting the financial burden of capital-intensive global clinical trials to the new entity. Kaveri Therapeutics intends to raise further capital to fund development efforts for treatments targeting lung, pancreatic, ovarian, and central nervous system cancers. The management team at Kaveri includes Chief Executive Officer Kristi Jones and Chief Medical Officer Dr. Robert Pierce.
Portfolio Strategy and Market Context
Both LNP7457 and LNP8701 have been highlighted at medical forums, including the American Society of Clinical Oncology meetings in 2025 and 2026, indicating preliminary data support. By moving these early-stage programs into a dedicated vehicle, Lupin is focusing its internal capital on other priorities while maintaining control through its majority stake.
On July 21, 2026, Lupin shares on the National Stock Exchange were trading at ₹2,504.60, representing a 1.05% gain over the previous day’s close of ₹2,478.50. The company currently commands a market capitalization of approximately ₹1.14 lakh crore and has seen its stock value rise by roughly 30% over the past year. High volume in buy orders during early trading suggests market participants have responded positively to the announcement.
Investor Monitorables
For investors, the success of this arrangement depends on Kaveri Therapeutics' ability to secure the necessary external funding to progress these drugs through human clinical trials. Because drug development in oncology carries significant execution risk and long timelines, the next key updates to track will be the progress of capital raising by Kaveri and any subsequent milestones reported for the clinical development of LNP7457 and LNP8701. Investors should also note that as a majority shareholder, Lupin’s financial statements may reflect the operational progress or future valuation changes of this subsidiary.